No abstract

In this study, a novel wavelet transform‐neural network method is presented. The presented method is used for the classification of grand mal (clonic stage) and petit mal (absence) epilepsies into healthy, ictal and interictal (EEGs). Preprocessing is included to remove an artifact occurred by blinking and a wandering baseline (electrodes movement) as well as an eyeball movement artifact using the Discrete Wavelet Transformation (DWT). Denoising EEG signals from the AC power supply frequency with a suitable notch filter is another job of preprocessing. The preprocessing enhanced speed and accuracy of the processing stage (wavelet transform and neural network). The EEGs signals are categorized into normal and petit mal and clonic epilepsy by an expert neurologist. The categorization is confirmed by the Fast Fourier Transform (FFT) analysis. The dataset includes waves such as sharp, spike and spike‐slow wave. Through the Countinous Wavelet Transform (CWT) of EEG records, transient features are accurately captured and separated and used as classifier input. We introduce a two‐stage classifier based on the Learning Vector Quantization (LVQ) neural network localized in both time and frequency contexts. The particular coefficients of the Continuous Wavelet Transform (CWT) are networks. The simulation results are very promising and the accuracy of the proposed method obtained is of about 80%.

No abstract

Background and objective Restless legs syndrome/Willis-Ekbom Disease (RLS/WED) is one of the most prevalent sleep disorders. There are contradicting data about the effectiveness of magnesium and vitamin B6 in alleviating the symptoms of this condition. Therefore, this study aimed to assess the efficacy of magnesium and vitamin B6 in alleviating the symptoms of RLS/WED. Methods A single-blind study was conducted on individuals with this illness for at least three months. Randomly, 75 patients were assigned into three groups: magnesium, vitamin B6, and placebo. The experimental group received daily doses of 40 mg vitamin B6 or 250 mg magnesium oxide. While others in the control group merely received a placebo. Patients’ disease severity and sleep quality were evaluated three times using standard questionnaires (at the beginning of the study, one and two months after therapy). Utilizing SPSS22 software and the ANOVA, t-test, and repeated measure tests, statistical analysis was conducted. Results The mean and standard deviation of sleep quality and disease severity at the beginning of the trial and throughout the first month following the intervention did not differ statistically between the three groups. In the second month following the intervention, the mean and standard deviation of sleep quality and disease severity were significantly different (P = 0.001). Conclusion Taking magnesium and vitamin B6 supplements can reduce the severity of symptoms of RLS/WED patients and improve their sleep quality.